The Risk of Herpes Zoster in Patients with Non-small Cell Lung Cancer according to Chemotherapy Regimens: Tyrosine Kinase Inhibitors versus Cytotoxic Chemotherapy
Cancer Research and Treatment. 2019;51(1):169-177 
Monoclonal Antibodies Versus Tyrosine Kinase Inhibitors Concurrent with Chemotherapy in Non–Small-Cell Lung Cancer: Exploring Divergent Results
Clinical Lung Cancer. 2008;9(3):141-143
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis
Medical Oncology. 2015;32(2):
P2-048: Activity of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in chemotherapy-pretreated non-small cell lung cancer (NSCLC) patients (pts) prospectively selected according to specific molecular predictive factors
Journal of Thoracic Oncology. 2007;2(8):S509
Chemotherapy of advanced non-small-cell lung cancer: A randomized trial of three cis-platin-based chemotherapy regimens
Lung Cancer. 1990;6(1-2):58
408P Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation
Annals of Oncology. 2020;31:S1402
Selection of non-small cell lung cancer patients for intercalated chemotherapy and tyrosine kinase inhibitors
Radiology and Oncology. 2017;51(3):241-251
Comparison of alternating to nonalternating chemotherapy regimens for non-small cell lung cancer
Lung Cancer. 1987;3(1):50
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
Scientific Reports. 2016;6(1):
A randomised trial of two cisplatin-containing chemotherapy regimens in patients with Stage III-B and IV non-small cell lung cancer
Lung Cancer. 1995;13(3):350